CanceRx 2014

A conference of the MIT Laboratory for Financial Engineering

In collaboration with the National Cancer Institute
and with the participation of the American Cancer Society
and the American Association for Cancer Research

Dedicated to the Memory of Thomas A. Tombrello

October 26-28, 2014
Cambridge, MA

CanceRx 2014 is an invitation-only conference hosted by MIT focusing exclusively on new approaches to financing biomedical innovation in oncology and other areas. The conference will bring together representatives from key stakeholder communities including academia and medical research centers, community hospitals, the biopharma industry, health plans, NIH/NCI, the FDA, patient advocacy groups, investment banks, hedge funds, credit rating agencies, biotech VCs, and institutional and retail investors.

The conference will be organized as a series of panel discussions—with substantial audience participation—devoted to addressing the funding challenges facing academia and the biopharma industry, including:

• Updates on fundraising initiatives and their business models since CanceRX 2013
• Recent scientific and clinical breakthroughs and potential business implications
• Financial modeling techniques for managing biopharma assets and liabilities
• Innovations in intellectual property rights management and licensing structures
• The changing role of government, patient advocacy groups, and philanthropy

In addition, an optional executive education program, “Basic Financial Analysis for Life Sciences Professionals,” will be offered from 1:00 to 5:00pm on Sunday October 26, followed by the welcome dinner at 6:00pm. Space for this educational program is limited to 100 participants on a first-come-first-served basis.

On Tuesday, September 23, 2014 Tom Tombrello, passed away. In addition to being a member of our Steering Committee, Tom played a key role in getting the CanceRx initiative launched. I was first introduced to Tom by his brother-in-law and my MIT colleague, Bob Merton. A physicist by training and trade, Tom turned his attention to cancer research after losing his daughter, Kerstin Arusha, to pancreatic cancer in 2008. In addition to providing very constructive feedback to my co-authors and me on our first paper on megafund financing, Tom introduced me to a number of key contacts in the oncology research and clinical communities, and invited me to participate in a rather unusual USC/NCI-sponsored conference at Cold Spring Harbor Laboratory in 2012. This conference—co-organized by David Agus, Danny Hillis, Parag Mallick, and Tom—brought together scientists, clinicians, venture capitalists, and one economist for three days of meetings to brainstorm about new approaches to cancer. The idea for CanceRx 2013 was born at this meeting, thanks to a number of the participants who not only welcomed my participation but patiently tutored me in the latest thinking about the challenges and opportunities for developing cancer therapeutics. Tom continued to provide support and encouragement thereafter in so many ways—more introductions to key stakeholders in the cancer community, many conference calls and email exchanges, ideas for business structures and potential pitfalls to guard against, and so on. Those who know Tom will understand the kind of impact that he has on the people around him, and I and our Steering Committee benefited enormously from his energy and wisdom. It’s hard to imagine a world without Tom in it, but we look forward to making the most of this conference as he would have wanted.

It is, therefore, only fitting that the Steering Committee dedicate the CanceRx 2014 Conference to the memory of Professor Thomas A. Tombrello.

– Andrew W. Lo, and on behalf of the CanceRx 2014 Steering Committee

View the Caltech press release
View LA Times article

David B. Agus is a professor of medicine and engineering at the University of Southern California Keck School of Medicine and Viterbi School of Engineering and heads U.S.C.’s Westside Cancer Center and the Center for Applied Molecular Medicine. He is one of the world’s leading cancer doctors, and the co-founder of two pioneering personalized medicine companies, Navigenics and Applied Proteomics. Dr. Agus is an international leader in new technologies and approaches for personalized healthcare and chairs the Global Agenda Council on Genetics for the World Economic Forum. He has received numerous awards, including the 2009 Geoffrey Beene Foundation’s Rockstar of Science Award. Dr. Agus’ first book, The End of Illness, was published in January 2012 by the Free Press Division of Simon & Schuster and is a New York Times #1 best seller. A PBS documentary called “The End of Illness with David Agus” aired nationwide in the fall of 2012.

Margaret Anderson is the executive director of FasterCures, a center of the Milken Institute and an action tank driven by a singular goal—to save lives by speeding up and improving the medical research system.She is a founding board member and past-president of the Alliance for a Stronger FDA, is a member of the NIH National Center for Advancing Translational Sciences (NCATS) Advisory Council and Cures Acceleration Network Review Board, the National Health Council Board of Directors, United for Medical Research Steering Committee, and the Institute of Medicine’s Forum on Drug Discovery, Development and Translation. Previously, Anderson was the deputy director and a team leader in the Center on AIDS & Community Health at the Academy for Educational Development, where she led public health projects; program director at the Society for Women’s Health Research; health science analyst at the American Public Health Association, where she managed a programmatic portfolio on HIV/AIDS and other sexually transmitted diseases, infectious diseases, women’s health, and public health infrastructure issues; and analyst and project director at the Congressional Office of Technology Assessment in the Biological Applications Program, where she studied societal and business implications of genetic testing. Anderson holds a bachelor’s degree from the University of Maryland and a master’s degree in science, technology, and public policy from George Washington University.

Christopher P. Austin, M.D., was appointed the first permanent director of the National Center for Advancing Translational Sciences (NCATS) in September 2012 by NIH Director Francis S. Collins, M.D., Ph.D.

Austin, who served as director of the NCATS Division of Pre-Clinical Innovation since the creation of the Center in December 2011, is leading NCATS in its mission to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. Austin is applying his experience across the spectrum of translational research to identify commonalities among diseases and implement a system-wide approach to accelerating the translational science process, thus speeding the delivery of interventions that improve human health.

Austin came to NIH in 2002 from Merck, where his work focused on genome-based discovery of novel targets and drugs. He began his career at NIH as the senior advisor to the director for translational research at the National Human Genome Research Institute, where he initiated the Knockout Mouse Project and the Molecular Libraries Roadmap Initiative. Other NIH roles have included serving as director of the Therapeutics for Rare and Neglected Diseases program as well as the NIH Chemical Genomics Center and as scientific director of the NIH Center for Translational Therapeutics.

Austin earned an A.B. summa cum laude in biology from Princeton University and an M.D. from Harvard Medical School. He completed clinical training in internal medicine and neurology at Massachusetts General Hospital, and a research fellowship in genetics at Harvard.

Edward Benz graduated from Harvard Medical School in 1973 and received his training at Brigham and Women’s Hospital and the National Institutes of Health. He is president of Dana-Farber Cancer Institute, CEO of Dana-Farber/Partners CancerCare, director and principal investigator of Dana-Farber/Harvard Cancer Center, and a member of the Governing Board of Dana-Farber/Children’s Cancer Center. He is also a clinical hematologist and an active NIH-funded investigator. In addition, he is the Richard and Susan Smith Professor of Medicine, Professor of Pediatrics, and Professor of Pathology at Harvard Medical School. Dr. Benz’s research focuses on the molecular pathology of hemolytic anemias.

Douglas A. Dachille is one of the founders of First Principles Capital Management, LLC (FPCM) and currently serves as Chief Executive Officer and Chief Investment Officer. His background and knowledge encompass all aspects of asset management, structured finance, and risk management. Immediately prior to co-founding FPCM, Mr. Dachille was President and Chief Operating Officer of Zurich Capital Markets Inc. (“ZCM”), an integrated alternative investment asset management and structured product subsidiary of Zurich Financial Services.

Preceding his tenure at ZCM, Mr. Dachille was a Managing Director for J.P. Morgan where he was the Global Head of Proprietary Trading and a member of the Management Committee of the Investment Bank. He was responsible for building the Global Relative Value Proprietary Trading business, and in fiscal year 2000 this business was one of the most important contributors to both the pre-tax net income and economic value for J. P. Morgan. In addition, Mr. Dachille was responsible for managing the bank’s investment portfolios, for developing and executing economic and regulatory capital management strategies, and for designing and managing non-qualified employee deferred compensation plans. Mr. Dachille was Chairman of the firm’s Capital Committee and served as a trustee of the J. P. Morgan qualified benefit plans. Prior to his role in the Proprietary Positioning business, Mr. Dachille was responsible for building the Hybrid Derivatives business for J. P. Morgan beginning in 1991. The Hybrid Derivatives business was developed to provide clients with customized derivatives solutions to complex problems and continues to be a significant revenue contributor for J. P. Morgan.

Mr. Dachille earned his Bachelor of Science in a special joint program through Union University and Albany Medical College, and later was a Pew Scholar in Medicine, Arts and Social Sciences at the University of Chicago.

Margaret Foti is CEO of the American Association for Cancer Research (AACR). During her tenure, AACR has grown to 34,000 members in more than 90 countries. She previously was managing editor of the journal Cancer Research and publisher for AACR. Foti is past president of the Society for Scholarly Publishing and the Council of Science Editors. Among her many professional activities, Foti serves as a board member and past-president of the National Coalition for Cancer Research. She is also a member of the executive committee and board of Friends of Cancer Research, a board member of the Greater Philadelphia Chamber of Commerce and its Life Sciences Congress, a medical advisory board member of the Prevent Cancer Foundation, and a council member of the European Association for Cancer Research.

Foti has received numerous honors for her contributions to cancer research, including the European CanCer Organisation Lifetime Achievement Award, the inaugural Kripke Legend Award for contributions to the advancement of women in the field and the American Society of Clinical Oncology’s Special Recognition Award. Most recently, she received the Stanley P. Reimann Honor Award from Fox Chase Cancer Center in Philadelphia in May 2013, and in March 2013 she was honored with the Distinguished Partner in Hope Award during the Annual Colorectal Cancer Conference hosted by the Abramson Cancer Center of the University of Pennsylvania in Philadelphia. She holds a B.A., M.A. and Ph.D. from Temple University and has been awarded several honorary doctorate degrees.

Jacob Goldfield is a successful option trader who retired as a senior partner of Goldman Sachs. He was later the Chief Investment Officer of Soros Fund Management and Quantum. He has invested and served as a board member for several private biotech companies in the past including serving as Chairman of the Board of CombinatorX Inc. Mr. Goldfield holds an A.B. in physics from Harvard College.

Peter D. Hancock is an Executive Vice President of AIG and was named Chief Executive Officer of AIG Property Casualty in March 2011, when the division was reorganized into two major global groups, commercial and consumer. Mr. Hancock, who joined AIG in 2010, had previously served as Executive Vice President, Finance, Risk, and Investments.

Mr. Hancock has spent his entire career in financial services, including 20 years at J.P. Morgan, where he established the Global Derivatives Group, ran the Global Fixed Income business and Global Credit portfolio, and served as the firm’s Chief Financial Officer and Chief Risk Officer. He co-founded and served as President of Integrated Finance Limited, an advisory firm specializing in strategic risk management, asset management, and innovative pension solutions. He joined AIG from KeyCorp, where he was Vice Chairman, responsible for Key National Banking.

Mr. Hancock is a member of the board of the Japan Society and is a William Pitt Fellow of Pembroke College, Cambridge.

Mr. Hancock was raised in Hong Kong and later attended Oxford University, where he earned his Bachelor of Arts degree in politics, philosophy, and economics.

H. Robert Horvitz received the Nobel Prize in Physiology or Medicine in 2002. He is the David H. Koch Professor of Biology at the Massachusetts Institute of Technology (MIT); an Investigator of the Howard Hughes Medical Institute; Neurobiologist (Neurology) at the Massachusetts General Hospital; and a Member of the MIT McGovern Institute for Brain Research; and a Member of the MIT Koch Institute for Integrative Cancer Research.

Dr. Horvitz received S.B. degrees in Mathematics and in Economics from MIT in 1968. He performed his graduate studies at Harvard University in the laboratories of Drs. James Watson and Walter Gilbert and received his Ph.D. in Biology in 1974. Dr. Horvitz then joined Dr. Sydney Brenner as a postdoctoral fellow at the Medical Research Council Laboratory of Molecular Biology in Cambridge, England. Since 1978, Dr. Horvitz has been an Assistant, Associate and Full Professor in the Department of Biology at the Massachusetts Institute of Technology. His research involving C. elegans has helped define evolutionarily conserved molecular genetic pathways important in human biology and human disease, including the pathway responsible for programmed cell death, or apoptosis.

Dr. Horvitz is a member of the Board of Trustees of the Massachusetts General Hospital and is Chairman of the Board of Trustees of the Society for Science and the Public. He was President of the Genetics Society of America. He has served on many editorial boards, visiting committees and advisory committees. He was co-chair of the National Cancer Institute Working Group on Preclinical Models for Cancer and a member of the National Human Genome Research Institute Advisory Council, of the U.S. National Academies of Science and Institute of Medicine Committee on Guidelines for Human Embryonic Stem Cell Research and of the American Academy of Arts and Sciences Committee on Advancing Research in Science and Engineering. He is a member of the Advisory Committee to the Director of the National Institutes of Health and of the Council of the U.S. Institute of Medicine.

Dr. Horvitz received the U.S. National Academies of Science Award in Molecular Biology; the Charles A. Dana Award for Pioneering Achievements in Health; the Ciba-Drew Award for Biomedical Science; the General Motors Cancer Research Foundation Alfred P. Sloan, Jr. Prize; the Gairdner Foundation International Award; the March of Dimes Prize in Developmental Biology; the Genetics Society of America Medal; the Bristol-Myers Squibb Award for Distinguished Achievement in Neuroscience; the Wiley Prize in the Biomedical Sciences; the Peter Gruber Foundation Foundation Genetics Prize; the American Cancer Society Medal of Honor; the Alfred G. Knudson Award of the National Cancer Institute; and the U.K. Genetics Society Mendel Medal.

Dr. Horvitz is a member of the U.S. National Academy of Sciences, the U.S. Institute of Medicine and the American Philosophical Society and is a Foreign Member of the Royal Society of London. He is a Fellow of the American Academy of Arts and Sciences and of the American Academy of Microbiology. Dr. Horvitz received an Honorary M.D. from the University of Rome and Honorary D.Sc. degrees from Cambridge University and Pennsylvania State University.

Dr. Horvitz has been a consultant to the Novartis Institutes for Biomedical Research and the venture capital company MPM Capital as well as to a number of biotechnology companies, and he cofounded the biotechnology companies NemaPharm, Inc., Idun Pharmaceuticals, Enlight BioSciences and Epizyme, Inc.

Robert Langer is an Institute Professor at MIT (there are 14 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member). He has written approximately 1,200 articles. These articles have been cited over 80,000 times; his h-index of 139 is the highest of any engineer in history. He has 815 issued and pending patents worldwide. His patents have licensed or sublicensed to over 250 companies. He served as Chairman of the FDA’s SCIENCE BOARD (it’s highest advisory board) from 1999-2002. His over 200 awards include both the United States National Medal of Science and the United States National Medal of Technology and Innovation, the Charles Stark Draper Prize (considered the engineering Nobel Prize), Albany Medical Center Prize (largest US medical prize), the Wolf Prize for Chemistry, the Millennium Technology Prize, the Priestley Medal (highest award of the American Chemical Society), the Gairdner Prize and the Lemelson-MIT prize, for being “one of history’s most prolific inventors in medicine.” He holds 20 honorary doctorates including honorary degrees from Harvard and Yale. Langer is one of the very few individuals ever elected to the Institute of Medicine, the National Academy of Engineering and the National Academy of Sciences.
Photo Credit: Stu Rosner.

Pablo Legorreta founded Royalty Pharma in 1996, after creating and managing two “proof of principle” investment vehicles in 1993 and 1994 that invested in royalty interests in two leading biotechnology products, and currently serves as Chief Executive Officer. Prior to founding these investment vehicles, Mr. Legorreta spent ten years at Lazard Frères where he provided cross-border merger and acquisition and corporate finance advisory services to US and European corporations. Mr. Legorreta joined Lazard Frères et Cie in Paris in 1988, then moved to Lazard Frères & Co in New York in 1990. Mr. Legorreta currently serves as a Director of Giuliani SpA and is a founding member of Boston Children’s Hospital Medical Research Council, as well as a member of the Board of Trustees of The Allen-Stevenson School, the Park Avenue Armory and of the American-Austrian Foundation/Open Medical Institute. He received a degree in industrial engineering from Universidad Iberoamericana.

Judy Lewent was responsible for worldwide financial, corporate development and licensing matters, as well as for strategic planning at Merck. Judy was also responsible for the Johnson & Johnson Merck Consumer Pharmaceuticals and Merial (Merck and Sanofi-Aventis) joint venture relationships and the Merck ongoing relationships with Astra and DuPont. She was Chairman of Merck Capital Ventures. Judy was a member of Merck’s Executive Committee, a senior management group which evaluates and makes strategic decisions for the Company.

Judy joined Merck in 1980 as Director, Acquisitions and Capital Analysis. She was promoted to Assistant Controller of the Merck Research Laboratories in 1983 and to Executive Director of Financial Evaluation and Analysis in 1985. Judy was elected Vice President and Treasurer in October 1987, Vice President for Finance and Chief Financial Officer in March 1990, Senior Vice President and Chief Financial Officer in December 1992, and Executive Vice President and Chief Financial Officer in February 2001. In January 2003, Ms Lewent gained additional responsibilities as President, Human Health Asia. Beginning in July 2005, Ms. Lewent resumed the title of Executive Vice President and Chief Financial Officer as she assumed strategic planning responsibilities for Merck, at which time she relinquished her role as President of Human Health Asia.

Judy is a member of the Board of Directors of GlaxoSmithKline, Motorola Solutions, and Thermo Fisher Scientific. Judy was a director of Motorola from 1995 to 2010 and a director of Dell from 2001 to 2011. Judy is a Class A Non-Executive Director of a group of privately held pharmaceutical companies, including Purdue Pharma, Mundipharma and Napp Pharmaceuticals. She is a trustee of the Rockefeller Family Trust; a life member of the MIT Corporation; and a member of the American Academy of Arts & Sciences.

Judy earned a B.S. in Economics from Goucher College in 1970 and an M.S. in Management from MIT’s Sloan School of Management in 1972. She received an Honorary Doctorate of Humane Letters from Goucher College in 1998, an Honorary Doctorate of Engineering from Stevens Institute of Technology in May 2000, and an Honorary Doctorate of Science from the New Jersey Institute of Technology in January 2004.

J. Leonard Lichtenfeld is Deputy Chief Medical Officer for the American Cancer Society. Among his responsibilities is directing the Society’s Cancer Control Science Department. This group of internationally recognized experts focuses on the prevention and early detection of cancer, as well as emerging science and trends in cancer. The department is responsible for producing the Society’s widely recognized guidelines for the prevention and early detection of cancer, including the role of nutrition and physical activity. In addition, Dr. Lichtenfeld oversees the Society’s cancer control programs in health equities, global health and our preventive health partnership with the American Heart Association and the American Diabetes Association.

Dr. Lichtenfeld is a board certified medical oncologist and internist who was a practicing physician for nearly 20 years. He has been active for many years in medical affairs on a local, state and national level. He has a long-standing interest in legislative and regulatory issues related to medicine, and serves on several national committees focused on physician payment, the quality of medical care and the role of health information technology in healthcare delivery.

A graduate of the University of Pennsylvania and Hahnemann Medical College (now Drexel University College of Medicine) in Philadelphia, Dr. Lichtenfeld completed his postgraduate training at Temple University Hospital in Philadelphia, Johns Hopkins University School of Medicine in Baltimore, and the National Cancer Institute in Bethesda, Md. He is a member of Alpha Omega Alpha, the national medical honor society, and has received several awards from medical organizations in recognition of his contributions to the practice of medicine. Dr. Lichtenfeld is married and resides in Atlanta and Thomasville, Ga.

Frank McCormick is director of the University of California San Francisco (UCSF) Comprehensive Cancer Center and Cancer Research Institute, a multidisciplinary research and clinical care organization that is one of the largest matrix cancer centers in the Western United States. A native of Cambridge, England, he received his B.Sc. in biochemistry from the University of Birmingham (1972) and his Ph.D. in biochemistry from the University of Cambridge (1975). Postdoctoral fellowships were held in the U.S. at the State University of New York at Stony Brook and in London at the Imperial Cancer Research Fund. He has been a Fellow of the Royal Society since 1996. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms, including positions with Cetus Corporation (Director of Molecular Biology, 1981-90; Vice President of Research, 1990-91) and Chiron Corporation, where he was Vice President of Research from 1991-92. In 1992 he founded Onyx Pharmaceuticals and served as its Chief Scientific Officer until 1996. McCormick’s current research interests center on the fundamental differences between normal and cancer cells that can allow the use of naturally occurring and engineered viruses as novel therapeutic strategies. Most recently, his work has focused on the adenovirus d11520, which lacks the gene E1b, an inhibitor of p53, and can therefore be exploited to selectively target cancer cells lacking p53. In addition to his position as director of the UCSF Cancer Center, Frank McCormick holds the David A. Wood Chair of Tumor Biology and Cancer Research in UCSF’s Department of Microbiology and Immunology. Dr. McCormick is the author of more than 200 scientific publications.

Robert C. Merton is the School of Management Distinguished Professor of Finance at the MIT Sloan School of Management.

He is the University Professor Emeritus at Harvard University, and was the George Fisher Baker Professor of Business Administration (1988–98) and the John and Natty McArthur University Professor (1998–2010) at Harvard Business School. He previously served on the finance faculty of MIT Sloan from 1970 to 1988. Dr. Merton co-founded Long-Term Capital Management. He is currently resident scientist at Dimensional Fund Advisors, where he is developing a next-generation, integrated pension-management solution system that addresses the deficiencies associated with traditional defined-benefit and defined-contribution plans.

Dr. Merton received the Alfred Nobel Memorial Prize in Economic Sciences in 1997 for a new method to determine the value of derivatives. He is past president of the American Finance Association, a member of the National Academy of Sciences, and a Fellow of the American Academy of Arts and Sciences.

He is the author of Continuous-Time Finance and a co-author of Cases in Financial Engineering: Applied Studies of Financial Innovation; The Global Financial System: A Functional Perspective; Finance; and Financial Economics. Dr. Merton also has been recognized for translating finance science into practice. He received the inaugural Financial Engineer of the Year Award from the International Association of Financial Engineers in 1993, which also elected him a Senior Fellow. Derivatives Strategy magazine named him to its Derivatives Hall of Fame as did Risk magazine to its Risk Hall of Fame. He also received Risk’s Lifetime Achievement Award for contributions to the field of risk management. A Distinguished Fellow of the Institute for Quantitative Research in Finance and a Fellow of the Financial Management Association, Dr. Merton received the Nicholas Molodovsky Award from the CFA Institute.

Dr. Merton holds a BS in engineering mathematics from Columbia University, an MS in applied mathematics from the California Institute of Technology, and a PhD in economics from MIT.

Lita Nelsen is the Director of the Technology Licensing Office at MIT, where she has been since 1986. This office manages over 600 new inventions per year, negotiating over 100 licenses per year, and helping to start 25 new startups.

Ms. Nelsen earned B.S. and M.S. degrees in Chemical Engineering from MIT and an M.S. in Management from MIT as a Sloan Fellow. Prior to joining the MIT TLO she spent 20 years in industry, primarily in the fields of membrane separations, medical devices, and biotechnology.

Ms. Nelsen was the 1992 President of the Association of University Technology and was a founding board member of MIHR, an organization concerned with the use of IP in medical research for developing country diseases.

Ms. Nelsen is widely published in the field of technology transfer and university/industry collaborations. She is a co-founder of Praxis, the UK University Technology Transfer Training Programme for which she was made a Member of the British Empire.

Larry Norton is Deputy Physician-in-Chief for Breast Cancer Programs at Memorial Sloan-Kettering and Medical Director of the Evelyn H. Lauder Breast Center.

His research concerns the basic biology of cancer; the mathematics of tumor causation and growth; and the development of approaches to better diagnosis, prevention, and drug treatment of the disease. He is involved in many areas of research including identifying the genes that predispose people to cancer or that cause cancer, developing new drugs, monoclonal antibodies that target growth factor receptors, and vaccines. A major milestone in his research career was the development of an approach to therapy called “dose density,” or “sequential dose density.” This is a new and more effective way of using anticancer drugs, based on a mathematical model he developed with his colleagues, which maximizes the killing of cancer cells while minimizing toxicity.

He is currently the principal investigator of a program project grant from the National Cancer Institute (NCI) that is aimed at better understanding breast cancer in the laboratory and in bringing these advances into clinical practice.

On a national level, Dr. Norton was formerly the Chair of the Breast Committee of the NCI’s Cancer and Leukemia Group B. He was also President of the American Society of Clinical Oncology (ASCO) from 2001 to 2002, and was appointed by President Clinton to serve on the National Cancer Advisory Board (the board of directors of the NCI).

Among many awards over the course of his career, he received ASCO’s highest honor, the David A. Karnofsky Award, and was McGuire Lecturer at the San Antonio Breast Cancer Symposium. He is an author of more than 350 articles and many book chapters, have served as a visiting professor throughout the United States, Canada, South America, Europe, Israel, and Asia, and also have trained many cancer doctors and researchers.

After receiving his M.D. from the College of Physicians and Surgeons, Columbia University, Dr. Norton trained in Internal Medicine at the Albert Einstein College of Medicine.

J. Marty Tenenbaum is the Founder and Chairman of Cancer Commons, a non-profit, open science community that compiles and continually refines information about cancer subtypes and treatments, based on the literature and actual patient outcomes.

Dr. Tenenbaum’s background brings a unique perspective of a world-renowned Internet commerce pioneer and visionary. He was founder and CEO of Enterprise Integration Technologies, the first company to conduct a commercial Internet transaction (1992), secure Web transaction (1993) and Internet auction (1993). In 1994, he founded CommerceNet to accelerate business use of the Internet. In 1997, he co-founded Veo Systems, the company that pioneered the use of XML for automating business-to-business transactions. Dr. Tenenbaum joined Commerce One in January 1999, when it acquired Veo Systems. As Chief Scientist, he was instrumental in shaping the company’s business and technology strategies for the Global Trading Web. Post Commerce One, Dr. Tenenbaum was an officer and director of Webify Solutions, which was sold to IBM in 2006, and Medstory, which was sold to Microsoft in 2007. Dr. Tenenbaum was also the Founder and Chairman of CollabRx, a provider of Web-Based applications and services that help cancer patients and their physicians select optimal treatments and trials, which was acquired by Tegal in 2012.

Earlier in his career, Dr. Tenenbaum was a prominent AI researcher and led AI research groups at SRI International and Schlumberger Ltd. Dr. Tenenbaum is a fellow and former board member of the American Association for Artificial Intelligence, and a former consulting professor of Computer Science at Stanford. He currently serves as a director of Efficient Finance, Patients Like Me, and the Public Library of Science, and is a consulting professor of Information Technology at Carnegie Mellon’s new West Coast campus. Dr. Tenenbaum holds B.S. and M.S. degrees in Electrical Engineering from MIT, and a Ph.D. from Stanford.

Thomas A. Tombrello earned his BA, MA and PhD degrees at Rice University in Houston. He came to Caltech in 1961, and except for a brief stint on the Yale faculty, has been here since then. A full professor of physics since 1971, Dr. Tombrello also served as Vice President and Director of Research at Schlumberger-Doll Research from 1987 to 1989. He was William R. Kenan, Jr. Professor at Caltech in 1997–2011, and was chair of the Division of Physics, Mathematics and Astronomy in August 1998–2008. He was also the Institute’s Technology Assessment Officer 1996-2010. In 2012 he was named the Robert H. Goddard Professor of Physics.

Dr. Tombrello and his research group are primarily involved in applying the techniques of theoretical and experimental physics to problems in materials science, surface physics, and planetary science. His ongoing research includes understanding the damage processes caused by megavolt ions in solids, microfluidic circuit elements, and non-linear financial phenomena.

He is a consultant for Schlumberger Ltd., Applied Minds Inc., FormFactor Inc., Lawrence Livermore National Laboratory, and University of Southern California. He is on the Board of Directors of the American Friends of Uppsala University and a Trustee of the London Institute for Mathematical Sciences – both non-profits.

Jake Xia joined Harvard Management Company (HMC) as Managing Director and Chief Risk Officer in June 2013. In this role, Mr. Xia manages risk exposure arising from both the internal and external investment portfolios.

Prior to joining HMC, Mr. Xia spent 17 years at Morgan Stanley, serving most recently as Head of Global Structured Rates Trading in New York and managing trading groups across the globe, including New York, London, Tokyo, Hong Kong, and Sydney. Prior to this role, Mr. Xia was Head of Global Fixed Income Trading Risk in New York where he was responsible for trading risks in all fixed income products, including interest rates, foreign exchange, emerging markets, credit, and real estate securities. Previously, Mr. Xia served as Morgan Stanley’s co-head of Fixed Income in Japan where he was also a member of Morgan Stanley’s 10-person Global Fixed Income Operating Committee, Asia Executive Committee, and Tokyo Management Committee. Prior to joining Morgan Stanley, Mr. Xia served as Vice President of Fixed Income Research at Salomon Brothers and was a research scientist at Schlumberger-Doll Research.

Mr. Xia holds a PhD in electrical engineering and computer science from Massachusetts Institute of Technology.

* Session Moderator

Christopher Austin, National Center for Advancing Translational Sciences (NCATS). Please see Steering Committee tab for bio.

François-Henri Boissel, a securitization banker and entrepreneur, is cofounder and CEO of Novadiscovery, a consulting company specialized in quantitative modeling & simulation applied to pharmaceutical R&D, incorporated in 2010. Novadiscovery has developed a unique framework to evaluate a drug asset based on the in-silico prediction of real-life clinical outcomes from the early phases of R&D. This technology enables drug companies to make better resources allocation decisions and establish a drug’s proof-of-commercial relevance upstream with a view to build a convincing value proposition for regulators and payers.

François-Henri started his professional career in 2004 with Lehman Brothers in London and subsequently Tokyo. In London, he helped launch the bank’s European non-performing loans (NPL) securitization operations. Acting in a principal capacity, he was involved in a variety of securitization deals, from whole business securitizations (nursing homes, telecom towers, etc.) to commercial and residential mortgages and consumer finance loans securitizations. In Asia, he closed the first residential NPL securitization deal in Malaysia. He was also heavily involved in the debt restructuring of the world’s largest Build-Operate-Transfer project in Taiwan, amounting to $13bl of refinancing to term out the OpCo’s liabilities and hedge its long-term inflation risk.

François-Henri earned an M.B.A. from ESSEC Business School (Paris).

Rena M. Conti, PhD, is an expert on the financing, regulation and organization of medical care, with an emphasis on the biopharmaceutical market and oncology practice. She is an Assistant Professor of Health Policy at the University of Chicago in the Department of Pediatrics, section of hematology/oncology, and the Department of Public Health Sciences where she teaches University-wide graduate level courses in the Economics and Regulation of the Biopharmaceutical Industry and Health Economics. Dr. Conti is a 2007 graduate of the Harvard University Interfaculty Initiative in health policy (economics concentration). She currently serves on the Government Affairs committee, the American Society of Clinical Oncology and is co-director of the economics working group for the Cancer Therapy Evaluation Program, National Cancer Institute.

Doug Criscitello leads Grant Thornton’s public sector financial institutions business unit and focuses on issues residing at the intersection of government and banking. Previously, Doug was chief financial officer at the Department of Housing & Urban Development, appointed by President Obama, where he directed the execution of HUD’s financial management program, including analytical work involving the department’s credit and insurance programs. Before HUD, his prior position in the public sector was as founding director of the New York City Independent Budget Office, a municipal government agency designed to provide nonpartisan, objective research and analysis of NYC’s budget. Prior to IBO, Doug spent a decade in the federal government focused on credit and insurance programs at both the Office of Management and Budget and at the Congressional Budget Office. Immediately prior to his appointment at HUD, he worked in JPMorgan’s Financial Institutions Group, where he provided operational, investment banking, and financial advisory services to U.S. government agencies and related entities along with multilateral development banks based in Washington DC.

Doug Dachille, First Principles Capital Management. Please see Steering Committee tab for bio.

Duncan N. Darrow is Chairman of the New Fund Institute for Collaborative Cancer Research which is a non-profit that provides funding packages to a handful of the most highly regarded anti-cancer drug hunters who are based at the country’s most acclaimed academic research centers. An NFI award requires the scientists to work collaboratively for a decade and for their research center to agree that all new drugs generated by the collaboration will be monetized by NFI, with proceeds then returned to the research centers. Twelve years ago, after his mother died of cancer, Duncan also established a charity that provides professional counseling and other supportive care to newly-diagnosed cancer patients on Long Island (www.fightingchance.org); for this work he has been recognized in a Wall Street Journal profile (6/25/12) and in a Proclamation issued by the New York State Assembly. Duncan and his wife, Wendy, who is a journalist, split their time between New York City and Sag Harbor. Duncan also has been a Wall Street lawyer for 40 years and at present is senior counsel with the firm of Sidley Austin LLP.

Ann Dewitt is Senior Director of Investments at Sanofi-Genzyme Bioventures. Ann joined SGBV in 2013 with a background in biotech partnering and early stage investment. Prior to SGBV, Ann was Senior Director, Corporate Development at Permeon Biologics and led a collaboration with a large pharmaceutical partner. Previously, Ann was a Senior Associate at Flagship Ventures, an early stage venture capital firm investing in healthcare companies with over $900 million under management and was a Board observer for several portfolio companies. While at Harvard, she was an entrepreneur-in-residence at Highland Capital Management and a founding team member of Novophage Therapeutics (now Sample6). Post-doctorate, she worked at 3M Company in corporate research and in business units, including 3M Pharmaceuticals, and was a Technical Circle of Excellence Award winner.

Ann is also on the Life Sciences Council of Springboard Enterprises, an organization dedicated to building high-growth technology-oriented companies led by women. She holds a B.S. from the University of Illinois Urbana-Champaign, a Ph.D. from MIT in systems biology, and an M.B.A. from Harvard Business School.

Dr. Joseph DiMasi is Director of Economic Analysis at the Tufts Center for the Study of Drug Development. The Center is an independent non-profit multidisciplinary research organization affiliated with Tufts University that is committed to the exploration of scientific, economic, legal, and public policy issues related to pharmaceutical and biotechnology research, development, and regulation throughout the world. Dr. DiMasi serves on the editorial board of Therapeutic Innovation and Regulatory Science, and has previously served on the editorial boards of the Drug Information Journal, the Journal of Research in Pharmaceutical Economics, and the Journal of Pharmaceutical Finance, Economics & Policy. Dr. DiMasi is an internationally recognized expert on the economics of the pharmaceutical industry. He has published in a wide variety of economic, medical, and scientific journals, and has presented his research at numerous professional and industry conferences. Dr. DiMasi testified before the U.S. Congress in hearings leading up to the FDA Modernization Act of 1997 and reauthorization of the Prescription Drug User Fee Act.

Dr. DiMasi’s research interests include the R&D cost of new drug development, clinical success and phase attrition rates, development and regulatory approval times, the role that pharmacoeconomic evaluations have played in the R&D process, pricing and profitability in the pharmaceutical industry, innovation incentives for pharmaceutical R&D, and changes in the structure and performance of the pharmaceutical and biotechnology industries.

Stephen Fawell recently joined AstraZeneca as Head of Oncology iScience with responsibility for target selection, drug discovery and optimization and plays a supporting role in translation efforts.

Steve obtained his Ph.D. at the University of Leeds UK, traveled to the US for a post-doctoral fellowship at Rutgers Medical School and then returned to the UK to the Imperial Cancer Research Fund (now CR-UK) in London. In 1990, he returned to the United States again, this time to join the biotechnology company Biogen where after forming and leading the oncology group at Biogen, Steve became Head of the Oncology Research Groups for the newly merged Biogen Idec, Inc. In his 15 years at Biogen Idec, Steve was involved in work associated with AvonexTM and AngiomaxTM, and his team took four new oncology drugs to IND and into clinical trials. In 2005, he joined Novartis Oncology (NIBR) as Drug Discovery Head in Cambridge, and in this role he led efforts that resulted in four INDs and supported an impending NDA. Steve joined Merck in 2010 as Vice President and Worldwide Franchise Discovery Head for Oncology, with responsibility for all preclinical Oncology Discovery and Strategy. During his stay at Merck the group advanced an ERK and HDM2 inhibitor and a PD1 mAb (KeytrudaTM) into the clinic.

Jose Maria Fernandez is the Director General of the Treasury at Spain’s General Secretariat of the Treasury and Financial Policy, within the Ministry of Economy and Competitiveness. His responsibilities include the issuance and management of Spain’s Central Government Debt, its risk and liability management, the treasury and cash operations, the coordination of Spain’s regional government public issuers, the Treasury’s IT and Resources management and a multiplicity of other public sector related financing programs.

Prior to his current position, Jose-Maria worked at MIT’s Laboratory for Financial Engineering developing securitization models for biotech R&D portfolios and for Kendall Rho LLC, a finance innovation firm. In addition to this, he has substantial experience in capital markets. He ran the Debt Capital Markets Global Origination department for Sovereigns, Supranational and Development Agencies at Credit Agricole Corporate and Investment Bank and he worked in, and led for three years, the Funding and Debt Management Department at the Spanish Treasury. Jose-Maria has also worked for the World Bank as a securities and debt capital markets expert, consulting for emerging governments on topics related to public debt issuance and management strategy.

Jose-Maria holds an MBA degree from MIT Sloan (Sloan Fellows Program in Innovation and Global Leadership), a Masters in Finance degree from the London Business School, a Masters in Portfolio Management degree from I.E.B. and Bachelor’s Degree in Economics and Business from CUNEF (Madrid). He was appointed State Economist and Trade Expert of the Spanish General Government in 1997.

Sandra Matrick Forman is a senior counsel at Proskauer in the Capital Markets Group, based in their New York office. Her practice focuses on representing investment companies, including business development companies (BDCs) and their investment advisors/management companies/sponsors, as well as investment banks raising capital for BDCs. She is one of a select group of lawyers who actively represent BDCs. Sandra also regularly counsels investment companies and public companies regarding their corporate governance and compliance issues.

Prior to joining Proskauer, Sandra worked at Harris & Harris Group as General Counsel, Chief Compliance Officer and Director of Human Resources (since August 2004) and as Corporate Secretary (since January 2009). Previously, she was an attorney in the Investment Management Group at Skadden, Arps, Slate, Meagher & Flom.

Sandra was an intern in the office of the General Counsel of the United States Department of Defense, Office of the Secretary of Defense, and for the Honorable Ronald S. Lew of the United States Federal District Court, Central District of California.

She was recently named a 2014 Woman of the Year by the National Association of Professional Women. She is actively involved in various boards and organizations, and serves the Jewish Federation of Northern New Jersey as Vice Chair of its Identity, Continuity and Engagement Committee and a member of its Central Planning and Allocation Committee.

John Frishkopf serves as a Managing Director, Treasurer, and Head of Asset Management at NewStar Financial. He also serves as a member of the firm’s Management and Underwriting Committees. He oversees the funding of the firm’s balance sheet, including the successful structuring and placement of nine securitizations totaling nearly $4 billion. Mr Frishkopf has 27 years of experience in the domestic and international debt capital markets. Prior to co-founding the Company, he was a Managing Director of Milford Associates, LLC, a turnaround and corporate restructuring advisory firm, which he started in 1999. The firm has worked in the United States and in Europe providing financial and operational turnaround and restructuring advice to middle-market companies as well as workout advice to lenders in a range of industries. In 1999, he was appointed Executive Vice President and Chief Financial Officer of VSZ, a.s. Kosice (the Slovak Steel Company) where he played a key role in its successful restructuring. In 1992, he co-founded Benson Oak & Company an investment banking boutique operating in the Czech and Slovak Republics. As a partner and lead transactor, he advised on the structuring and placement of over $4 billion of debt transactions. Prior to Benson Oak, he was a vice president at Citicorp’s North American Investment Banking and International Corporate Finance Division where he spent five years working in capital markets, originating, structuring and placing securitization, loan and private placement deals. Mr. Frishkopf is a member of the board of directors of the National Brain Tumor Society and an advisor to Accelerate Brain Cancer Cure. He holds a B.S. from the Massachusetts Institute of Technology and an M.M.S. from the MIT Sloan School of Management.

Ilan Ganot is Founder, CEO and member of the board of directors for Solid Ventures. Prior to starting Solid, Mr. Ganot was an investment banker at JPMorgan Chase in London, specializing in hedge funds driven equities business for the firm. Ilan also work at Nomura Securities in London, Hong Kong and New York and Lehman Brothers in Europe.

Mr. Ganot embarked on a banking career after practicing law at leading Israeli firm, Haim Zadok & Co, where his focus was private equity law and mergers and acquisitions. Mr. Ganot was a captain in the Israel Defense Forces. Mr. Ganot received his MBA from London Business School and holds law and business degrees from the IDC in Herzliya, Israel.

Michael Goldberg graduated Summa Cum Laude with a Hon. B.Sc. in Biological Chemistry from the University of Toronto and received an M.Phil. in BioScience Enterprise from the University of Cambridge. Dr. Goldberg completed his Ph.D. in Biological Chemistry under the supervision of Institute Professor Robert Langer at the Massachusetts Institute of Technology, where he was a member of the founding class of the Harvard-MIT Division of Health Sciences and Technology’s Graduate Education in Medical Sciences program. His doctoral research focused on the synthesis, screening, and application of a novel class of materials for delivery of RNAi therapeutics. He pursued post-doctoral training in the laboratory of Institute Professor Phillip Sharp in the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology, where he worked to develop cancer-specific RNAi therapeutics targeting alternative splicing and synthetic lethality. Dr. Goldberg is presently an Assistant Professor in the Department of Cancer Immunology & AIDS at Dana-Farber Cancer Institute, Harvard Medical School. His lab creates novel drug delivery platforms for applications in cancer immunotherapy, as induction of antitumor immunity can lead to curative outcomes.

José-Carlos “JC” Gutiérrez-Ramos, Ph.D., is Senior Vice President and Head of BioTherapeutics Research & Development, within Pfizer Worldwide Research & Development. JC is passionate about the early and iterative use of experimental medicine approaches in discovery research, the continuous focus on scientific innovation and medical differentiation during drug discovery, and the “entrepreneurialization” of big pharma research groups.

Prior to joining Pfizer, JC was Senior Vice President and Head of the Immuno-inflammation Center for Drug Discovery (iiCEDD) at Glaxo Smith Kline. JC built the iiCEDD as a global group of “drug hunters” that included biologists, chemists, pharmacologists, protein scientists, clinicians and business developers who were responsible for drug discovery and development through Phase IIa (Proof of Concept). Chief achievements in the formation of the iiCEDD included entrepreneurial organizational and funding structure, the talent recruitment and identification of innovative discovery areas to focus on, which were poised for medical differentiation. The iiCEDD pipeline had a significant external component with 50 percent of its pipeline and activities achieved through external partnerships with biotech companies, academia and contract research organizations.

Prior to GSK José-Carlos served as Site Head and Chief Scientific Officer (CSO) at AMGEN Mountain View. Previous to the AMGEN acquisition of Avidia, he was the Senior Vice President of R&D, where he led a significant effort of novel protein therapeutics for autoimmune disease. Before his AVIDIA appointment, he served as CSO of Peptimmune Inc. in Cambridge, MA, where he was responsible for the development of peptide based therapeutics for autoimmune disease, including multiple sclerosis and diabetes. Before Peptimmune, JC served as Vice President, Inflammation at Millennium Pharmaceuticals, where he was responsible for advancing preclinical candidates in Inflammation & Immunology to human trials and advancing compounds (small molecules and antibodies) from discovery through clinical development.

JC was also part of the Faculty at the Genetics department of Harvard Medical School, where he led a major research team at the Center for Blood Research that generated more than 150 peer-reviewed publications. Before coming to the US, he was member of the Basel Institute for Immunology in Basel, Switzerland, and a fellow at the Max-Planck for Immunbiologie in Freiburg, Germany. JC received his master’s degree in Chemistry and his Ph.D. in Immunochemistry by the Autonoma University of Madrid, Spain.

Tyler Jacks is the Director of MIT’s Koch Institute for Integrative Cancer Research and the David H. Koch Professor of Biology at MIT. He has pioneered the use of gene targeting technology in the mouse to study cancer-associated genes and to construct mouse models of many human cancer types, including cancers of the lung, brain and ovary. His lab has made seminal contributions to the understanding of the effects of mutations of several common cancer-associated genes. This research has led to novel insights into tumor development, normal development and other cellular processes, as well as new strategies for cancer detection and treatment.

Jacks has published more than 200 scientific papers. He has served on the Board of Scientific Advisors of the National Cancer Institute (NCI) and the Board of Directors of the American Association of Cancer Research (AACR); he is also a past president of the AACR. He is currently chair of the National Cancer Advisory Board. Jacks is a member of the Board of Directors of Amgen and Thermo Fisher Scientific and an advisor to several biotechnology and pharmaceutical companies.

In recognition of his contributions to the study of cancer genetics, he has received numerous awards, including the AACR Outstanding Achievement Award, the Amgen Award from the American Society of Biochemistry and Molecular Biology, the Chestnut Hill Award for Excellence in Medical Research, the Paul Marks Prize for Cancer Research and in 2013 was named one of the MGH’s Cancer Center’s One Hundred. He was elected to both the National Academy of Sciences and the Institute of Medicine of the National Academies in 2009, the American Academy of Arts and Sciences in 2012, and the inaugural class of Fellows of the AACR Academy in 2013. Jacks was a Merck Fellow of the Helen Hay Whitney Foundation, a Markey Scholar, a Searle Scholar, and is currently a Daniel K. Ludwig Scholar in Cancer Research and a Howard Hughes Medical Institute Investigator. Jacks received his BA in biology from Harvard College in 1983. His PhD thesis was performed with Harold Varmus at the University of California, San Francisco. He served as post-doctoral fellow in Robert Weinberg’s lab at the Whitehead Institute at MIT and joined the MIT faculty in 1992.

Alan L. Jakimo, senior counsel in Sidley Austin’s New York office, works in the corporate, securities, venture, and technology fields, with emphasis in the life science and information science industries. Mr. Jakimo’s experience encompasses a broad range of transactions in venues spanning the Americas, Asia, and Europe and involving financial institutions and operating enterprises along the spectrum from start-up to seasoned. The interplay among finance, technology development, and licensing of intellectual property rights plays a key role in many of Mr. Jakimo’s assignments. He serves as a Special Professor of Law at Hofstra Law School, where he teaches a course on the influence of law and regulation on the discovery, development, and commercialization of regulated medical products.

Edward Jung founded Intellectual Ventures after leaving Microsoft Corporation where he was chief architect and advisor to executive staff. At Intellectual Ventures, he also serves as the chief technology officer, setting strategic technology and new business models for the company.

At Microsoft, Mr. Jung managed projects relating to web platforms, semantic web technology, intelligent operating systems, adaptive user interfaces and artificial intelligence. He co-founded many Microsoft teams including Windows NT, Microsoft Research, mobile and consumer products, and web services. Before joining Microsoft in February 1990, Mr. Jung founded the Deep Thought Group, working on neural network chips for learning and parallel computation. His biomedical research work in the 1980s in protein structure and function was published in several journals including the Proceedings of the National Academy of Sciences and the Journal of Biochemistry.

An avid inventor, Mr. Jung holds more than 700 patents worldwide and has over 1,000 patents pending. His inventions are in the areas of biomedicine, computing, networking, energy, and material sciences.

Mr. Jung has served as an advisor to Harvard Medical School, the Fred Hutchinson Cancer Research Center and the Institute for Systems Biology and consulted to the Asia Pacific Federation, the Aspen Institute, the China Academy of Sciences, the National Academy of Sciences, and the World Health Organization.

Jeb Keiper was recently appointed Chief Business Officer of Nimbus Discovery, a Series A biotech firm based in Cambridge, MA.

Prior to joining Nimbus Discovery, Jeb was Vice President (VP) of Business Development for GSK Oncology and a member of the Oncology Executive team as well as the Worldwide Business Development Leadership Team. In this role, Jeb was responsible for defining and executing the business development strategy for GSK Oncology, including in‐licensing transactions, acquisitions, strategic alliances, academic research relationships, alliance management and competitive intelligence. Alongside these responsibilities, Jeb was also named to lead the GSK-Novartis integration of the commercial oncology business valued at $16B and impacting thousands of staff across 80+ countries.

Jeb joined GSK in 2005 as RADEX Secretary for R&D Chairman Moncef Slaoui. In 2008, he moved to Worldwide Business Development (WWBD) where he held multiple roles in early- and late-stage licensing opportunities, commercial collaborations, out-licensing, newco spinouts, and public and private equity transactions. Jeb also helped to establish the WWBD Transactions Centre of Excellence for GSK as Head of Acquisitions and Divestments.

Prior to joining GSK, Jeb worked in business development at Boston-based TransForm Pharmaceuticals (bought by J&J in 2005 for $230 million), as well as for McKinsey & Company, a management consultant firm serving pharma and biotech clients. Jeb began his career at Pfizer Central Research as a chemist. He received four degrees from the Massachusetts Institute of Technology (MIT) in Chemistry, two in Chemical Engineering, and an M.B.A. from the MIT Sloan School of Management with joint program in Biomedical Enterprises with Harvard Medical School.

Manolis Kellis is a Professor of Computer Science at MIT, a member of the Computer Science and Artificial Intelligence Laboratory and of the Broad Institute of MIT and Harvard, where he directs the MIT Computational Biology Group. His group works at the interface of computational and experimental genomics, and has pioneered methods for characterizing the regulatory elements of the human genome, and their role in human disease using comparative genomics, epigenomics, and regulatory genomics. His group has helped lead the integrative analysis efforts of several large-scale genomics projects, including the NIH Roadmap Epigenomics project, the ENCODE project, the comparative analysis of 29 mammals, and the Genotype Tissue-Expression (GTEx) project. He has received the US Presidential Early Career Award in Science and Engineering (PECASE), the NSF CAREER award, the Alfred P. Sloan Fellowship, and was recognized as a top young innovator by Technology Review, Genome Technology, and the Boston Museum of Science. He obtained his Ph.D. from MIT, where he received the Sprowls award for the best doctorate thesis in computer science. Prior to computational biology, he worked on artificial intelligence, machine vision, robotics, and computational geometry, at MIT and at the Xerox Palo Alto Research Center. He lived in Greece and France before moving to the US.

Gary J. Kelloff, MD has had over 40 years in cancer research at the National Cancer Institute (NCI), authoring more than 400 publications. Dr. Kelloff is a graduate of the University of Colorado (BS and MD degrees). After post-graduate training in medicine at Emory University, he began his NCI career as an intramural scientist and section head in viral immunology working on retroviruses and oncogenes. After fifteen years in NCI’s intramural program he moved to what is now the Division of Cancer Prevention (DCP), where he developed a basic science, translational research, and clinical development program in chemoprevention. Since 2001, he has been a special advisor for the NCI Division of Cancer Treatment and Diagnosis working on strategies for developing imaging-based and clinical biomarkers for oncology drug development and cancer patient management. He previously led and currently leads several collaborations with FDA and the pharmaceutical industry on drug development strategies and co-chairs on-going efforts under the Foundation for the National Institutes for Health Biomarkers Consortium to define biomarker use in cancer drug development and patient management. Past work has included establishment of a developmental pathway for approval of cancer prevention drugs as part of an AACR initiative and evaluation of tumor burden markers (PSA-doubling time prostate cancer, Ca-125 in ovary) and precancerous histopathology (colorectal adenomas) as part of a C Change initiative. Current efforts under the Biomarkers Consortium include consideration of functional and molecular imaging (FDG-PET/CT, volumetric CT, DW-MRI, molecular probes) and new technologies for measuring circulating tumor cells, minimal residual disease, novel trial designs for evaluating prognostic and predictive biomarkers, molecular signatures and new drugs, including gene expression and proteomic biomarkers. All this work has involved collaboration with leaders in industry, academia, and the pharmaceutical industry and has resulted in many publications addressing specific biomarkers and general drug development strategies.

S.P. Kothari is Deputy Dean and Gordon Y Billard Professor of Accounting and Finance at the Sloan School of Management. As Deputy Dean, he has responsibility for all of Sloan’s faculty, approximately 200 (hiring, promotion and tenure, performance evaluation, and compensation), and half a dozen research centers based in Sloan.

Previously, he served as global head of equity research for Barclays Global Investors (BGI), responsible for research supporting BGI’s active equity strategies, from 2008-09. The actively managed equity portfolio had in excess of $100 billion in assets, and the research team was comprised of approximately 50 PhDs based in San Francisco, London, and Sydney.

Earlier, Kothari was Head of the Department of Economics, Finance, and Accounting at the MIT Sloan School of Management. This department included approximately 75 professors and lecturers and an administrative staff.

Kothari’s highly cited research focuses on financial reporting and valuation, asset allocation, explaining the diversity in international accounting practices, use of employee stock options for compensating executives and accounting for stock options, evaluating investment performance, and corporate uses of derivatives for hedging and speculation. The American Accounting Association (AAA) honored his work with the 2014 Notable Contributions to Accounting Literature Award. For the past 17 years, Kothari has served as an editor of the Journal of Accounting & Economics, a world-renowned academic research journal in accounting. He is an expert on economic policy issues in India and has written numerous opinion-page editorials in The Economic Times.

Kothari has frequently served as a senior consultant with Charles River Associates (www.crai.com), a business-economics and litigation-support consulting firm. He has consulted with many large corporations, including leading U.S. and international banks and asset management companies, Australian television broadcast corporations, U.S. steel companies, E&Y, KPMG, PriceWaterhouse Coopers, and the U.S. Department of Justice. Kothari served on the Board of VVisions (http://vvisions.com/) from 1998-2004 and is currently on the Board of FIA Global (http://www.fiaglobal.com/).

Kothari received his BE (Hons.) from the Birla Institute of Technology & Science, Pilani; his MBA from the Indian Institute of Management, Ahmedabad; and his PhD from the University of Iowa. He has also received an honorary doctorate, Doctor Honoris Causa, from the University of Technology, Sydney, in May 2013, and a Distinguished Alumnus Award from Birla Institute of Technology and Science, Pilani, in 2013.

Eric Lander is a geneticist, molecular biologist and mathematician, who pioneered many of the key concepts for discovering the genes underlying human diseases and helped to bring them into reality as one of the principal leaders of the international Human Genome Project.

He is Founding Director of the Broad Institute of Harvard and MIT, as well as Professor of Biology at MIT and Professor of Systems Biology at Harvard. Previously, he directed the Whitehead/MIT Center for Genome Research, the largest center in the Human Genome Project.

His research has ranged over all aspects of the human genome — including the genetic basis of inherited diseases and cancer, human population history, evolutionary forces, regulatory elements, long non-coding RNAs, and three-dimensional folding of the genome.

The recipient of numerous awards, he was elected a member of the US National Academy of Sciences and Institute of Medicine.

Dr. Lander was appointed by President Obama to co-chair the President’s Council of Advisors on Science and Technology, which advises the White House on matters including health, manufacturing, energy, communications, nanotechnology and national security.

Dr. Lander earned his BA from Princeton and PhD from Oxford as a Rhodes Scholar. He has co-founded several successful biotechnology firms.

Clifton Leaf is Deputy Managing Editor at Fortune, where he helps oversee the magazine as well as edits major features. A former Executive Editor at Fortune, Cliff rejoined the magazine in October 2013 after a six-year hiatus. During that time he served as a guest editor for The New York Times op-ed page and Sunday Review and, prior to that, as Executive Editor at SmartMoney magazine.

A winner of the Gerald Loeb Award for Distinguished Business and Financial Journalism and a two-time finalist for the National Magazine Award, Cliff has devoted much of the past decade to a cause somewhat removed from business journalism: trying to change the way the global war on cancer is funded and pursued. That effort culminated in his well-received book, The Truth in Small Doses: Why We’re Losing the War on Cancer—and How to Win It, which was published by Simon & Schuster in the summer of 2013.

A keynote or featured speaker at more than three dozen scientific conferences around the world, Cliff has presented testimony to the President’s Cancer Panel three times, served on the national board of directors for Susan G. Komen for the Cure, the world’s largest breast cancer charity, and delivered “Grand Rounds” at the National Cancer Institute. He is a recipient of the NIHCM’s Health Care Journalism Award, the Andrew Heiskell Community Service Award, and several leadership honors from patient organizations. And this July, the European School of Oncology gave Cliff its first Lifetime Achievement Award for cancer reporting, “in recognition of his contribution over more than a decade to opening up informed and critical debate about the way cancer research efforts are organized and conducted.”

Prior to joining Fortune in 2000, Cliff was an editor and writer for a number of national magazines. A graduate of Williams College, he later received a Master of Fine Arts in writing from Sarah Lawrence College. He lives in Brooklyn, New York, with his wife, filmmaker Alicia Slimmer, and their 10-year-old daughter, Sofia.

Pablo Legorreta, Royalty Pharma. Please see Steering Committee tab for bio.

Bruce N. Lehmann is a professor of finance and economics in the Graduate School of International Relations and Pacific Studies of the University of California, San Diego. Prior to joining IR/PS in 1992, he was on the faculty of the Department of Economics and the Graduate School of Business at Columbia University for eleven years. Professor Lehmann is a specialist in financial economics, with expertise in the pricing of capital assets, their volatility, and the markets in which they trade. His main research interests include empirical tests of asset pricing models, the analysis of short-run stock price fluctuations, and the microstructure of securities markets, with recent emphasis on the behavior of Japanese financial markets. Lehmann is the author of numerous articles in leading scholarly journals, including the Journal of Finance; the Journal of Financial Economics; Macroeconomic Dynamics; the Quarterly Journal of Economics; and the Journal of Econometrics. He is also the author of the entry “Empirical Testing of Asset Pricing Models” in the New Palgrave Dictionary of Money and Finance. Lehmann is founding co-editor of the Journal of Financial Markets and has served as associate editor of the Review of Financial Studies and the Review of Quantitative Finance and Accounting. He has served as a director of the Western Finance Association, a member of the Scientific Advisory Board of Investment Technology Group, Inc. and on the boards of directors of First Boston Investment Funds, Inc. and of BEA Associates, Inc. Lehmann currently serves on the Investment Advisory Board of the University of California Retirement System and Endowment and on the Investment Committee of the UC San Diego Foundation. He has earned many honors and distinctions: he was a Batterymarch Fellow, the most prestigious award given to scholars in finance; an Olin Fellow at the National Bureau of Economic Research; and a National Fellow at the Hoover Institution on War, Revolution and Peace at Stanford University. He is the only person to receive all three distinctions. He is currently actively exploring early stage drug development based on the megafund concept.

He earned his A.B. in economics and history magna cum laude from Washington University and his M.A. and Ph.D. degrees in economics from the University of Chicago.

Judy Lewent. Please see Steering Committee tab for bio.

Dr. Aili (Alison) Li is a Portfolio Manager in Asset Allocation/Risk Management at the California Public Employees’ Retirement System (CalPERS). At CalPERS, the Asset Allocation unit is responsible for strategic as well as tactical asset allocation of the Total Fund. Her work involves theory verification, hypothesis development, empirical testing of valuation framework and risk management for all asset classes in the Total Fund, including public and private equity, fixed income, real assets and hedge funds.

Before CalPERS, Dr. Li worked for WorldQuant LLC in 2012 as Vice President in Portfolio Management. She was in charge of building quantitative equity long-short strategies as part of a multi-billion dollar multi-strategy hedge fund.

From May 2007 to October 2010, Dr. Li was director of equity research at Symphony Asset management LLC. She was in charge of the entire quantitative equity investment process with three billion under management at its peak.

From September 2001 to May 2007, Dr. Li was quantitative equity strategist at Mellon Capital Management Corp. She built alpha factors for quantitative equity and global tactical asset allocation strategies.

From August 1998 to August 2001, Dr. Li was Assistant Professor of Accounting at the Hong Kong University of Science and Technology.

Dr. Li received her Ph.D. in Business Administration with concentration in Accounting and Finance from Haas School of Business, U.C. Berkeley. She received her Master in Economics from University of Southern California. She got her B.A. in Investment and Management from Renmin University of China.

Andrew W. Lo is the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management, the director of MIT’s Laboratory for Financial Engineering, a principal investigator at MIT’s Computer Science and Artificial Intelligence Lab, and an affiliated faculty member of the MIT Department of Electrical Engineering and Computer Science. He received his B.A. in economics from Yale University in 1980, his A.M. and Ph.D. in economics from Harvard University in 1984, and taught at the University of Pennsylvania’s Wharton School from 1984 until 1988 when he joined MIT’s faculty. He has authored many research articles (see http://alo.mit.edu) and several books including The Econometrics of Financial Markets, A Non-Random Walk Down Wall Street, and Hedge Funds: An Analytic Perspective. His most recent research interests include econometric methods for measuring and monitoring systemic risk, evolutionary and neurobiological models of investor behavior, and applications of financial engineering to support biomedical innovation and translational medicine.

Rosemarie Loffredo is the Chief Administrative Officer and Chief Financial Officer of Leukemia & Lymphoma Society (LLS). In her role, she ensures that LLS achieves the ambitious goals of its long-range strategic plan. Ms. Loffredo leads all administrative and staff functions, including finance, information technology and human resources, and she is responsible for enhancing LLS’s organizational efficiency and effectiveness in partnership with the organization’s executive team.

Earlier in her career, Ms. Loffredo served as interim chief financial officer for Pro Mujer International, a nonprofit organization dedicated to empowering disenfranchised women in Latin America through microfinance, healthcare and educational services. She previously served as vice president, financial operations and treasurer of New York University, the largest private research university in the U.S. She also served as senior vice president of finance for CA Technologies, Inc. (formerly Computer Associates), one of the world’s largest enterprise management software providers and prior to that position was vice president of treasury for International Paper Company. She previously held leadership positions with global banks in international treasury as well industry segment management including securities and commodities, capital-intensive industry and public finance. Ms. Loffredo currently serves on the board of directors of CenterLight Healthcare System.

Ms. Loffredo holds a bachelor’s degree in international economics, commerce and finance from Georgetown University, a master’s degree in economics from Boston College, and an M.B.A. in finance and international business from Columbia University.

Juan Carlos López was born in Oaxaca, México, in 1967. He obtained his first degree on Biomedical Research at the Universidad Nacional Autónoma de México, majoring in neuroscience. Juan Carlos got his Ph.D. degree from Columbia University (New York) in the laboratory of Eric Kandel, studying synaptic plasticity in neuronal cultures. He then carried out postdoctoral work at the Instituto Cajal (Madrid), studying presynaptic mechanisms of transmitter release. During this period, Juan Carlos wrote a book on the neurobiology of memory (“El Telar de la Memoria”, Algar Editorial), with which he won the IV European Award of Scientific Dissemination in 1998. Two years later, Juan Carlos left experimental research to become Editor of Nature Reviews Neuroscience in London. In January 2004, he returned to New York to become the Chief Editor of Nature Medicine.

In February 2014, Juan Carlos left the publishing industry to become Head of Academic Relations and Collaborations at Hoffmann-La Roche. In this role, he and his team are charged with fostering interactions of his company with academic institutions worldwide with the aim of promoting the advance of translational research and the discovery of new medicines.

Juan Carlos has also served as a member of the Scientific Advisory Board and of the Board of Directors of Noscira, a Spanish biotechnology company interested in neurodegeneration, and a member of the Board of Directors of the Eureka Institute, an international initiative that aims to promote translational research by fostering the education of MDs and PhDs interested in bridging the gap between bench and bedside.

Anna A. Makki is a Director within the Credit Suisse Asset Finance Group in New York, with ten years of capital markets and investment banking experience. She specializes in securitizing “off-the-run” asset classes, with a particular focus on monetizing pharmaceutical royalties. In her career, Anna has raised over $1.5 billion for clients including biopharmaceutical companies, research institutions, inventors and healthcare royalty investors.

Prior to joining Credit Suisse, Anna was an Executive Director within Morgan Stanley’s Global Capital Markets division, specializing in structured debt financings and intellectual property monetizations. Previously, she spent several years within Investment Banking where she focused on M&A and capital raising transactions for insurance clients. She started her investment banking career at Banc of America Securities in New York.

Anna graduated from Franklin & Marshall College, Magna Cum Laude and Phi Beta Kappa, with a B.A. in mathematics and business administration. She received a M.B.A. from The Wharton School and a M.A. from the Lauder Institute of Management & International Studies at the University of
Pennsylvania.

Parag Mallick’s primary appointment is as an Assistant Professor at Stanford University. Dr. Mallick received his undergraduate degree in Computer Science and Biochemistry from Washington University in St. Louis, and his graduate degree with David Eisenberg at UCLA. His postdoctoral research, with Ruedi Aebersold at the Institute for Systems Biology, focused on quantitative and clinical proteomics. His current research interests focus on development of tools for quantitative, proteome-scale analyses of protein structure and function and on the application of those tools to global profiling for predictive, personalized cancer diagnosis and prognosis. His research bridges the interface between experimental studies and analytic computational challenges.

Dr. Monique Mansoura is the Senior Director of the Medical Countermeasures Franchise at Novartis Vaccines (NVx) leading daily operations and policy for a cross-functional, global team with a portfolio of contracts that make Novartis one of the premier partners of the U.S. Government mission to development medical countermeasures in support of its critical role in national and global health security. She is an active member in leading multi-stakeholder coalitions working to strengthen these public-private partnerships that are central to this vital mission.

Dr. Mansoura has a passion and track record of success in building and developing high performing, cross-functional teams driven to tackle, design and drive complex missions of international importance with expertise at the interface of public-private partnerships, particularly in market-challenged environments. She has been a successful leader at top levels of Government and industry by building effective teams across diverse organizations, developing talent, leveraging multi-stakeholder networks through effective engagement with partners including senior leaders in the Executive Office of the President, executive branch agencies (HHS, DHS, DOD), Congress, industry, academia, patient advocacy organizations and state, local and international governments.

She trained under Francis Collins at the National Institutes of Health (NIH) during the peak of activity for the Human Genome Project (1996-2001) and following 9/11 and the anthrax attacks in 2001, took on leadership roles in National Health Security for the U.S. Government (USG). From 2002-2010 she drove strategic policy, programming and budgeting for a pioneering multibillion dollar medical countermeasure (MCM) development and acquisition program under the authorities of the Project BioShield Act of 2004 and the Pandemic and All-Hazards Preparedness Act of 2006. She led development of the inaugural Public Health Emergency Medical Countermeasure (PHEMCE) Strategy and Implementation Plan which provided the framework for priority-setting and a roadmap for the allocation of the $5.6 billion fund to enhance preparedness against chemical, biological, radiological and nuclear threats during the first decade of the program.

Dr. Mansoura earned a Ph.D. in Bioengineering and M.S. in Human Genetics from the University of Michigan and a B.S. in Chemical Engineering from Wayne State University. During a recent sabbatical, she earned an MBA in the MIT Sloan Fellows Program in Innovation and Global Leadership, served as a consultant to the MIT Center for Biomedical Innovation and supported program and planning efforts for the NIH Therapeutics for Rare and Neglected Diseases (TRND) program, now a part of the National Center for Advancing Translational Science (NCATS) at NIH.

Cyrus Mehta is President and co-founder of Cytel Corporation and Adjunct Professor of Biostatistics, Harvard University. Cytel is a leading provider of software and services for the design, interim monitoring and implementation of adaptive clinical trials. Dr. Mehta consults extensively with the biopharmaceutical industry on group sequential and adaptive design, offers workshops on these topics, and serves on data monitoring and steering committees for trials in many therapeutic areas including oncology, cardiology, neurology and metabolic disease. He has led the development of the StatXact, LogXact and East software packages that are widely used in the biopharmaceutical industry and at academic research centers. He publishes his methodological research in leading statistics journals and is a past co-winner of the George W. Snedecor Award from the American Statistical Association. He is a Fellow of the American Statistical Association and an elected member of the International Statistical Institute. He was named Mosteller Statistician of the Year by the Massachusetts Chapter of the American Statistical Association in 2000, and Outstanding Zoroastrian Entrepreneur by the World Zoroastrian Chamber of Commerce in 2002.

Michael Millette is the global head of the Structured Finance business in the Finance Group at Goldman Sachs. He is also co-chairman of the Structured Finance Capital Committee and serves on the Investment Banking Division Client and Business Standards Committee and the Bank Capital Committee. Michael joined Goldman Sachs in 1994 in Fixed Income and moved to the Finance Group in 1997. He was named managing director in 2002 and partner in 2006.

Prior to joining the firm, Michael worked as an analyst at Citibank and a portfolio manager at John Hancock.

Michael serves on the Board of Visitors for the School of Business and Economics of the Catholic University of America, the Board of Trustees of the Inner City Scholarship Fund, the Board of Directors of the Massachusetts Boys and Girls State Foundation, the Publication Committee of the Manhattan Institute, the Finance Committee of The Ursuline School, and the Advisory Board of the Boston College Center for Asset Management.

Michael earned an AB in History from Cornell University in 1987 and an MS in Finance from Boston College in 1994. He became a CFA charterholder in 1994.

Stewart C. Myers is the Robert C. Merton (1970) Professor of Finance at the MIT Sloan School of Management.

His research is primarily concerned with the valuation of real and financial assets, corporate financial policy, and the financial aspects of government regulation of business. Myers is the author of influential research papers on many topics, including adjusted present value, rate of return regulation, pricing and capital allocation in insurance, real options, and moral hazard and information issues in capital structure decisions. He is the co-author of the classic textbook, Principles of Corporate Finance, now in its 11th edition.

Myers is past president of the American Finance Association and an elected Fellow of the Financial Management Association. He also is a Research Associate of the National Bureau of Economic Research; a principal of the Brattle Group, Inc.; and a director of Entergy Corporation.

Myers holds an AB from Williams College and an MBA and a PhD from Stanford University.

Larry Norton, Memorial Sloan Kettering Cancer Center. Please see Steering Committee tab for bio.

Dr. Robert O’Neill is the Senior Statistical Advisor to CDER in the Office of Translational Sciences in the Center for Drug Evaluation and Research (CDER), Food and Drug Administration. Until June 2011 , Dr. O’Neill was the Director of the Office of Biostatistics which provides biostatistical and scientific computational leadership and support to all programs of CDER. Prior to October 1998 he was Director of the Office of Epidemiology and Biostatistics, responsible also for the post-market safety surveillance of new drugs. In 1989-1990, Dr. O’Neill was a visiting professor at the Department of Research, University Medical School, Basel, Switzerland, where he developed and presented numerous lectures and created a course series ‘Topics in Therapy Evaluation and Review ‘ (TITER) for European pharmaceutical scientists, which was the model for the European Course In Pharmaceutical Medicine (ECPM), a degree granting graduate program. Dr. O’Neill was the ICH FDA topics leader for two guidances, E9 and E5. He is a fellow of the American Statistical Association (1985) and the Society for Clinical Trials (2013), a member of several professional societies, a past Member of the Board of Directors of the Society for Clinical Trials, the 2002 recipient of the Marvin Zelen Leadership Award in Statistical Science, and the 2004 Lowell Reed Lecture Awardee from the American Public Health Association.

Karen Shaw Petrou was dubbed by the American Banker in 2012 the “sharpest mind analyzing banking policy today — maybe ever.”

She is the co-founder and Managing Partner of Federal Financial Analytics, Inc., a privately-held company that, since 1985, has provided analytical and advisory services on legislative, regulatory, and public-policy issues affecting financial services companies doing business in the U.S. and abroad. The firm’s practice is a unique blend of strategic advice and policy analysis that does not include lobbying or any other projects that would compromise its objectivity and independence. This, Petrou believes, gives boards of directors, senior management and regulators the best advice on emerging issues on which to base their own strategic planning and advocacy.

Ms. Petrou is a frequent speaker on topics affecting the financial services industry. In addition to presentations to Congress, foreign legislatures and government agencies, she has spoken before such organizations as the Japanese Diet, the Office of the Comptroller of the Currency, various Federal Reserve Banks, the Economist’s Buttonwood conference, the Securities Industry and Financial Markets Association, the American Bankers Association, The Clearing House, the Financial Services Roundtable, the Institute of International Bankers, the Conference of State Bank Supervisors, the American Bar Association, the Brookings Institution, the American Institute of Certified Public Accountants, the National Association of Manufacturers, and many other industry, academic and policy-maker audiences. She has also authored numerous articles in professional publications such as the American Banker and International Economy, as well as general-interest media like The New York Times and Wall Street Journal. Ms. Petrou appears frequently in the media as an expert on banking legislation and regulation.

Prior to founding her own firm in 1985, Ms. Petrou worked in Washington as an officer at Bank of America, where she began her career in 1977. She is an honors graduate in Political Science from Wellesley College and also was a special student in an honors program at the Massachusetts Institute of Technology. She earned an M.A. in that subject from the University of California at Berkeley, and was a doctoral candidate there. She has served on numerous boards of banking organizations and sits as a director on the board of the Foundation Fighting Blindness and as an advisory member of the board of the Morin Center for Banking and
Financial Law.

Syril Pettit is the Executive Director of the ILSI Health and Environmental Sciences Institute (HESI). HESI is a global, non-profit organization based in Washington, DC, that provides a platform for scientists from academia, government, industry, NGOs, and other research organizations to collaborate in addressing human and environmental health issues. HESI’s scientific initiatives develop multi-sector derived data and technical approaches to support improved public health via enhanced drug, chemical, environmental, and food safety and innovation. Syril is the senior staff leader of HESI’s efforts to engage scientists from more than 80 universities, 40 government agencies, and 50 companies from around the globe in its programs.

Syril provides scientific and strategic leadership to the organization’s 16 different technical programs in such areas as cardiovascular safety, genetic toxicology, risk assessment methodology, bioaccumulation, immunotoxicology, and more. As Executive Director, Syril works closely with HESI’s program 7 management staff in-house (all with advanced scientific degrees) as well as via interactions with the hundreds of scientific experts who participate in HESI’s international programs. She helps to ensure the technical rigor, efficiency, and balance of HESI’s initiatives as well as supporting efforts to ensure their effective communication to the scientific community.

Syril routinely speaks at international scientific meetings, as a lecturer at government and academic institutes, and has authored numerous scientific articles published in journals such as Science Translational Medicine, Toxicological Sciences, American Heart Journal, etc. Over the last year she launched HESI’s CITE (Combining Interdisciplinary and Translational Expertise) initiative that has helped establish HESI’s role in providing international thought-leadership and expertise in moving research to public health application across diverse sectors. Syril has been a staff member of HESI for 14 years and Executive Director since 2011. She holds a bachelor’s degree in Biology from Amherst College and a Master’s Degree in Environmental Management from the Duke University Nicholas School of the Environment. She served as a Counselor for the National Capital Area Chapter for the Society of Toxicology (for 5 years), and is currently a member of the Duke NSOE Alumni Counsel. She is an avid swimmer and marathoner.

Cathrin Petty joined J.P. Morgan in 2014 to co-head the healthcare team. She has extensive experience in the life sciences industry and has nearly twenty years experience in private equity, investment management and investment banking. She has invested over $1 billion in 28 companies in EU, US and India in the pharmaceutical, biotechnology, medical technology and generics sectors. Cathrin is a Non-Executive Director of Circassia Pharmaceuticals plc. She was recently a Non-Executive Director at ICON Plc and Non-Executive Director of the NHS Strategic Health Authority for Greater London.

Prior to joining J.P. Morgan, Cathrin was a Special Partner at Vitruvian Partners LLP, a Partner at Apax Partners LLP and Principal at Schroder Ventures Life Sciences. She holds an MA in Natural Sciences from the University of Cambridge and a post-graduate Diploma in Management Studies from the Judge Institute, Cambridge.

Tomas J. Philipson is the Daniel Levin Professor of Public Policy Studies in the Irving B. Harris Graduate School of Public Policy at The University of Chicago. He is an associate member of the Department of Economics and a former senior lecturer at the Law School. His research focuses on health economics, and he teaches Masters and PhD courses in microeconomics and health economics at the University.

Philipson was born and raised in Sweden where he obtained his undergraduate degree in mathematics at Uppsala University. He received his MA and PhD in economics from the Wharton School and the University of Pennsylvania. He was a visiting faculty member at Yale University in the academic year 1994-95 and a visiting fellow at the World Bank in the winter of 2003.

Philipson has served in several public sector positions. He served in the second Bush Administration as the senior economic advisor to the head of the Food and Drug Administration (FDA) during 2003-04 and subsequently as the senior economic advisor to the head of the Centers for Medicare and Medicaid Services (CMS) in 2004-05. He served as a senior health care advisor to Senator John McCain during his 2008 campaign for President of the United States. In December of 2010, he was appointed by the Speaker of the US House of Representatives to the Key Indicator Commission created by the recent health care reform.

Philipson is the recipient of numerous international and national research awards. He has twice (in 2000 and 2006) been the recipient of the highest honor of his field: the Kenneth Arrow Award of the International Health Economics Association (for best paper in the field of health economics). In addition, he was awarded the Garfield Award by Research America in 2007 (for best paper in the field of health economics), The Prêmio Haralambos Simeonidisand from the Brazilian Economic Association in 2006 (for best paper in any field), and the Distinguished Economic Research Award from the Milken Institute in 2003 (for best paper in any field of economics). Philipson has been awarded numerous grants and awards from both public and private agencies, including the National Institutes of Health, the National Science Foundation, the Rockefeller Foundation, the Alfred P. Sloan Foundation, the John M. Olin Foundation, and the Royal Swedish Academy of Sciences.
Philipson is a founding editor of the journal Forums for Health Economics & Policy of Berkeley Electronic Press and has been on the editorial board of the journal Health Economics and The European Journal of Health Economics. His research has been published widely in all leading academic journals of economics such as the American Economic Review, Journal of Political Economy, Quarterly Journal of Economics, Journal of Economic Theory, Journal of Health Economics, Health Affairs, and Econometrica.

Philipson is a fellow, board member, or associate of a number of other organizations outside the University, including the National Bureau of Economic Research, the American Enterprise Institute, the Manhattan Institute (where he is chairman of Project FDA), the Heartland Institute, the Milken Institute, the RAND Corporation, and the USC Shaeffer Center for Health Economics and Policy. At the University of Chicago, he is affiliated with the John M. Olin Program of Law & Economics, the George J. Stigler Center for the Study of the Economy and the State, the Northwestern/University of Chicago Joint Center for Poverty Research, the Population Research Center, and the National Opinion Research Center (NORC). He was a member of the University-wide Council on Research in 2000-02 and is currently a member of the Advisory Committee to the University’s Office of Intellectual Property and Technology Transfer (UCTech).

Philipson has done executive consulting for both private corporations, including many U.S. Fortune 100 companies, as well as government organizations domestically and internationally. This has included work for the President’s Council on Science and Technology, the National Academy of Sciences, and the UK National Health Service. It has also included work for multi-lateral organizations such as the World Bank, the World Intellectual Property Organization, and the OECD. He is the co-founder of Precision Heath Economics LLC, on the honorary board of directors of the internet-based consulting firm the Round Table Group, on the board of directors of MedErr Inc, on the board of the Center for Medicine in the Public Interest, on the council of advisors for the Gerson-Lehrman Group, and a consultant for Compass-Lexecon, Bates White, and Analysis Group.

Philipson’s research is frequently disseminated through the popular press. He is a monthly op-ed contributor for Forbes magazine and frequently appears in numerous popular media outlets such as CNN, CBS, FOX News, Bloomberg TV, National Public Radio, New York Times, Wall Street Journal, Business Week, The Economist, Washington Post, Investor’s Business Daily, and USA Today. He is a frequent keynote speaker at many domestic-and international health care events and conferences. Philipson has been selected for inclusion in The International Who’s Who in The World.

Leslie Platt, JD, is President of the nonprofit Innovation Financing Roundtable. Mr. Platt is a nationally recognized life sciences attorney and executive with significant senior-level experience in the public, private, and nonprofit sectors and substantial focus on innovation finance, impact investment, and public-private partnerships in the health and technology sectors.

Leslie has structured and negotiated numerous agreements regarding the financing, conduct, and commercialization of biomedical research, the financing and construction of research facilities and housing projects, and the protection, valuation, and transfer of intellectual property and technology. He has drafted many provisions enacted into law and has provided direction, counsel, and guidance on diverse U.S. and international public policy issues, projects, financings, management and personnel issues, and regulatory compliance matters.

Leslie is currently a Principal in Leslie Platt & Associates, LLC, where he has provided strategic advisory services to a leading biopharmaceutical company and other organizations. Mr. Platt previously served as Counsel at Pillsbury Winthrop Shaw Pittman LLP; Principal at Ernst & Young LLP; Chief Operating Officer and General Counsel of The Institute for Genomic Research (TIGR); and Senior Vice President and General Counsel at the American Type Culture Collection.

In the federal government, Leslie served as Executive Assistant to the Director and Chief of Operations, Office of the Director, at the National Institutes of Health; as Deputy General Counsel-Legal Counsel at the Department of Health and Human Services, and as Counsel and Staff Director of the White House Agent Orange Working Group. Leslie earlier served as Associate General Counsel for Legislation at the Department of Housing and Urban Development. Mr. Platt was a Charter Member of the Federal Senior Executive Service and has received a number of awards for distinguished public service.

Leslie also served for years as Board Chairman of the BIO-sponsored BioJudiciary Project and as Chair of the Loudoun County, VA Science & Technology Cabinet. Leslie has taught legal and ethical aspects of bioscience management at George Mason University. He has authored a number of articles and is a frequent lecturer at industry conferences in the U.S. and around the world.

Issi Rozen, director of strategic alliances at the Broad Institute of Harvard and MIT, is responsible for partnering with the pharmaceutical industry and venture investors and developing new scientific and business collaborations. He is also responsible for initiating and establishing new ventures around innovative research projects and for licensing the institute’s intellectual property portfolio. He joined the Broad in 2011 after a career in the pharmaceutical industry. Before joining the Broad Institute, Rozen was director of corporate development at Resolvyx Pharmaceuticals, a venture-backed biotech start-up, where he headed business development efforts. Before that, he led the business analysis group at EMD Serono where he was responsible for evaluations of in-licensing and M&A opportunities as well as commercial analytics and forecasting. In addition, Issi is also an accomplished jazz guitarist and has released three recordings. He earned his M.B.A. at MIT’s Sloan School of Management.

Tom Rutledge is Head of Origination and Sourcing at Magnetar Capital. Prior to joining Magnetar in 2008, Mr. Rutledge was an Executive Director in JPMorgan’s US Structured Credit group. Before that, he served in investment and risk management roles at several investment management firms, including positions as CIO for Fixed Income at OTA Asset Management, Head of Risk Management and Quantitative Analysis at Boldwater Capital, and Analyst at New Bond Trading. He was also Head of Flow Research and eResearch at Deutsche Bank. Mr. Rutledge began his career as a fixed income derivatives trader and marketer at Merrill Lynch in New York and London.

He has also served as an adjunct professor at Boston College’s Carroll School of Management, teaching a course in derivatives and risk management in the graduate finance program.

Mr. Rutledge received a BA in English from Amherst College and an MBA from the MIT Sloan School of Management.

David Sabow is a Managing Director and the Head of Silicon Valley Bank’s National Life Sciences and Healthcare practice. In this role, David manages the deal teams across the U.S. and is responsible for developing and executing on the Bank’s Life Sciences strategy. Silicon Valley Bank’s Life Sciences practice is the leading provider of financing, cash management, and investment management solutions for a wide range of private and public companies in the Emerging Therapeutic, Medical Device, Diagnostic, Digital Health and Healthcare Services sectors.

Prior to joining Silicon Valley Bank, David spent 8 years in the Life Sciences Investment Banking practice at Canaccord Genuity, where he participated in public financings and M&A transactions with an aggregate deal value in excess of $1 billion. While at Canaccord, David worked on both domestic and cross-border transactions across the spectrum of Life Sciences and Healthcare. David graduated with honors from Santa Clara University with a BS in Economics and a BA in French.

Ken Schaner has practiced law for over 40 years, representing many for-profit and non-profit entities in the corporate and tax aspects of a wide variety of agreements, transactions, financings, licenses, mergers and acquisitions.

Ken began his career at the Internal Revenue Service’s (IRS) legislative and regulations division. During his time with the IRS, Ken worked on the 1969 Tax Reform Act and was one of the principal drafters of the new private foundation provisions.

In 1982, Ken co-founded Swidler Berlin, LLP. While a partner in that firm, he also served as managing member and chair of the corporate group. After Swidler Berlin’s merger with Bingham McCutchen, LLP in 2006, Ken remained a partner until 2008, when he formed a new firm to focus on representing tax-exempt organizations.

Since 1983, Ken has served as general counsel to the Cystic Fibrosis Foundation (CFF). In that capacity, Ken represented CFF in its first venture philanthropy transaction with Aurora Biosciences Corporation (now Vertex). Since then, Ken has represented numerous clients in venture philanthropy transactions and related legal matters. Ken also serves as general and outside counsel to many non-profits. He advises on the full range of issues faced by Section 501(c)(3), (c)(4) and (c)(6) organizations, including board governance, business, and tax-exempt compliance issues.

David Schmittlein is the John C Head III Dean and Professor of Marketing at the MIT Sloan School of Management.

His focus has been to broaden MIT Sloan’s global visibility, to work with the faculty in creating new high-quality management education programs, to develop enhanced educational opportunities for current students, and to develop and disseminate business knowledge that has impact and that will stand the test of time. He also has reached out to the many members of MIT’s alumni community to gain their valuable insights on MIT Sloan and management education.

Prior to his appointment at MIT Sloan, Schmittlein was the Ira A. Lipman Professor and Professor of Marketing at the Wharton School of the University of Pennsylvania from 1980 until 2007. He also served as Interim Dean during July 2007 and as Deputy Dean from 2000 to 2007, and was chair of the editorial board for Wharton School Publishing. His research assesses marketing processes and develops methods for improving marketing decisions. He is widely regarded for his work estimating the impact of a firm’s marketing actions, designing market and survey research, and creating effective communication strategies.

Schmittlein has served as a consultant on these issues for numerous firms, including American Express, American Home Products, AT&T, Bausch & Lomb, Boston Scientific, Ford Motor Company, Gianni Versace S.p.A., Hewlett-Packard, Johnson & Johnson, Lockheed Martin, Pfizer, Revlon, Siebe PLC, the Oakland Raiders, The Quaker Oats Co., and Time Warner. His work has been published in leading journals in marketing, management, economics, and statistics. In addition, he has been an area editor for Marketing Science and a member of the editorial board for the Journal of Interactive Marketing, the Journal of Marketing Research, Marketing Letters, and Marketing Science.

Schmittlein serves on the International Advisory Board for Groupe HEC, the Governing Board of the Indian School of Business, the International Advisory Board of Lingnan (University) College of Sun Yat-sen University, and the Advisory Board for the School of Economics and Management of Tsinghua University. He has served on the World Economic Forum’s Global Agenda Council for Marketing and Branding. He has been a Visiting Professor in the Faculty of Economics at Tokyo University and a Distinguished Scholar in Residence at Washington University’s John M. Olin School of Business. Schmittlein has received awards for his research, his editorial work, and his teaching. His observations and research have been cited often in the popular press, including Advertising Age, Business 2.0, BusinessWeek, China.com, Computerworld, Fortune, NPR’s Marketplace, People’s Daily Online, Reuters,The ABC Evening News with Peter Jennings, The Economist, The Financial Times, The Los Angeles Times, The Philadelphia Inquirer, The New York Times, The Wall Street Journal, U.S. News & World Report, and USA Today.

Schmittlein holds a BA in mathematics from Brown University and an MPhil and a PhD in business from Columbia University.

Azita Sharif, an engineer and entrepreneur, is the founder and CEO of DSI, a bio-informatics firm, headquartered in Cambridge, MA, focusing on products and solutions for drug discovery, oncology, pathology bio-banking and transplant surgical applications. The technology her firm has developed enables drug companies to make better resources allocation for cohort development through Biobanking.

Azita started her career in the semiconductor industry as an R & D Engineer, and later as a Product Manager. From Engineering, she made the transition to high technology investment and was selected as a Kauffman Fellow. She served her fellowship at Advent International Global Private Equity in Boston. Since then, she has been involved with many startups and investment management programs in both the US and Argentina. She has advised a number of seed-stage start-ups on writing business plans and seeking venture funds. As a result of her efforts, a number of these companies were able to close funding and grew to a successful exit. Azita also worked on the start-up of a new venture fund, Triton Venture Management, ($45 M under management), in Austin, TX.

Since the mid-1990s, she has served as a judge in the annual International Moot Corp., MIT and Harvard Business Plan Competitions. She also served as a Director of the Executive Board of the Women’s Leadership Initiative at the JFK School of Government at Harvard. She is a member of Springboard Enterprises, an organization dedicated to building high-growth technology-oriented companies led by women. Azita is a graduate of The University of Texas at Austin, Fletcher School of Law and Diplomacy and Harvard Business School.

Phillip A. Sharp is Institute Professor (highest academic rank) at the Massachusetts Institute of Technology and member of the Department of Biology and the Koch Institute for Integrative Cancer Research. He joined the Center for Cancer Research (now the Koch Institute) in 1974 and served as its director for six years, from 1985 to 1991, before taking over as head of the Department of Biology, a position he held for the next eight years. More recently, he was founding director of the McGovern Institute, a position he held from 2000 to 2004. His research interests have centered on the molecular biology of gene expression relevant to cancer and the mechanisms of RNA splicing. His landmark work in 1977 provided the first indications of “discontinuous genes” in mammalian cells. The discovery fundamentally changed scientists’ understanding of gene structure and earned Dr. Sharp the 1993 Nobel Prize in Physiology or Medicine. Dr. Sharp has authored over 400 papers. He is an elected member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society, and the Royal Society, UK. Among his many awards are the Gairdner Foundation International Award, the Lasker Basic Medical Research Award and the National Medal of Science. His long list of service includes the presidency of the AAAS (2013) and Chair of the Scientific Advisory Committee, SU2C Project, AACR. A native of Kentucky, Dr. Sharp earned a B.A. degree from Union College, Barbourville, KY, and a Ph.D. in chemistry from the University of Illinois, Champaign-Urbana. Dr. Sharp is a co-founder of Biogen (now Biogen Idec) and Alnylam Pharmaceuticals Inc.

Greg Simon is the CEO of Poliwogg, a financial services company creating unique capital market opportunities in healthcare and life sciences. He has held senior positions in both chambers of Congress and the White House, been a senior strategy consultant to a variety of international technology CEO’s, led a national patient advocacy nonprofit he co-founded with Mike Milken and served as a senior executive at a large pharmaceutical corporation. He has developed a reputation as a visionary strategist, a dynamic public speaker and writer, and as a knowledgeable analyst of emerging trends in healthcare, information technology, innovative drug research and development and patient advocacy.

Darren Snellgrove is Chief Financial Officer, VP of Finance and Operations for Johnson & Johnson Innovation. This includes the Innovation Centers located in San Francisco, Boston, London, and Shanghai and the J&J Development Corporation (JJDC). Darren also provides financial support and leadership to Janssen Healthcare Innovation (JHI) and Janssen Labs. Darren is well suited for this role with a solid understanding of complex deal structures, value creation, external partner experience, and a proven track record of success in a variety of financial leadership positions. His diverse experience that spans multiple operating companies, sectors, and business development finance has positioned him well to build a dynamic portfolio of external relationships that will help drive innovation.

Prior to joining the J&J Innovation Organization, Darren was VP of Finance and Procurement, CFO at Janssen AI. In September 2009, as part of an agreement with Elan Corporation, Johnson & Johnson formed a new company that acquired substantially all of Elan’s assets and rights related to the Alzheimer’s Immunotherapy Program (AIP), a joint collaboration with Pfizer.

Darren has a proven track record in Finance at J&J. Darren joined J&J through the acquisition of Centocor in 1999. He spent three years at Centocor prior to the acquisition and three years after, in positions of increasing responsibility and in support of a variety of functions including Commercial, R&D, and Business Development.

In 2002, Darren moved to J&J Corporate, where he spent three years in the Mergers and Acquisitions Finance group providing financial leadership on more than 100 potential acquisitions, major licensing deals, equity investments, options, structures, and divestitures across all sectors. Following his time at Corporate, Darren spent two years in the Bay Area with Scios/ALZA as Commercial and R&D Controller before joining Cordis in 2007 and Janssen AI in September 2009.

Prior to becoming CFO at Janssen AI, he was Commercial Controller for the Cordis Franchise, providing financial leadership to the US Operating Board and the Commercial Leadership Team including U.S. Selling, Marketing, Business Operations, and Global Strategic Marketing.

Darren holds a B.A. Honors Degree in Economics and Philosophy from Southampton University in England, and an MBA from Villanova University. Last year he was selected to participate in J&J’s prestigious Accelerated Enterprise Leader Program. Darren has also completed Finance and Business Development Leadership Programs at both Harvard and Wharton.

Christiana Stamoulis is a senior executive in the biopharmaceutical industry, with extensive experience in developing strategies for sustainable growth, and expertise in the execution of complex M&A deals, strategic collaborations and capital raising transactions. She brings nearly 20 years of experience in the life sciences industry as a strategic and corporate finance advisor to CEOs and Boards of Directors of global biopharmaceutical companies, a senior executive and a director of a public company board.

Ms. Stamoulis currently serves as an independent director of the Board of Hologic Inc., (Nasdaq: HOLX; Market cap: $7 billion) a leading global developer, manufacturer and supplier of diagnostic products, medical imaging systems, and surgical products and is a member of the Audit Committee and the Corporate Development Committee.

For the past 4 years, Christiana was the Senior Vice President and Head of Corporate Strategy and Business Development at Vertex Pharmaceuticals (Nasdaq: VRTX; Market cap: $22 billion) and a member of Vertex’s Executive Team. She helped develop Vertex’s corporate vision of the future and led the development of strategies and initiatives to achieve this vision. She also led the identification, evaluation and execution of key business collaborations to enable Vertex to achieve its strategic objectives and position the company for sustainable long-term growth.

Prior to joining Vertex, Ms. Stamoulis spent nearly 15 years in the investment banking and management consulting industries. She was a Managing Director at Citigroup’s Investment Banking division and led the building of the firm’s Life Sciences group. Prior to Citigroup, Ms. Stamoulis was in the Healthcare Investment Banking Group at Goldman, Sachs & Co., where she spent the majority of her investment banking career. As an investment banker, she has advised clients and has led the execution of M&A and capital raising deals with aggregate value in excess of $100 billion.

Ms. Stamoulis started her professional career as a strategy consultant at The Boston Consulting Group where she advised clients on major strategy and organizational change initiatives. She holds an MBA from the Massachusetts Institute of Technology (MIT) Sloan School of Management with a concentration in Applied Economics and Finance, as well as two Bachelor of Science degrees, in Economics and Architecture, respectively, also from MIT.

Roger M. Stein has been actively engaged in developing, implementing and writing about new approaches to applied risk modeling and financial prediction for almost 25 years. He and his teams have developed, implemented and delivered products and services that have become industry benchmarks in banking and finance.

He is currently Senior Lecturer in finance at the MIT Sloan School of Management and also holds the position of Research Affiliate at the MIT Laboratory for Financial Engineering. He is also an Affiliated Researcher at the Center for Risk Management Research, University of California, Berkeley. His current research interests are in the areas of systemic risk, credit risk, model risk and validation, biomedical funding, and the interface between data mining and financial theory.

In addition to his academic work, he has held a number of senior positions in industry. He was the Chief Analytics Officer at State Street GX, as well as Senior Managing Director of Product Strategy. Before this he was Managing Director of Research and Academic Relations globally for Moody’s Corporation and prior to this he was President of Moody’s Research Labs (MRL), a wholly owned subsidiary of Moody’s Corporation, where he led a team of researchers and engineers charged with incubating a number of innovative quantitative technologies for assessing credit and other forms of financial risk. The firm’s research spanned diverse domains including mortgage-, municipal- and retail-credit risk, microfinance, and systemic risk. Upon reaching maturity, the products and methodologies incubated by MRL were transitioned to other operating units of Moody’s Corporation for ongoing production. Stein also headed the Managed Funds group at Moody’s Investors Service for several years during which time he introduced new quantitative approaches to various aspects of the ratings process.

Earlier in his career, Dr. Stein was co-head of research at Moody’s KMV. There he led the commercial development of risk management tools (including RiskCalc™ and LossCalc™) that are in use at hundreds of financial institutions worldwide, as well as creating customized analytic services for clients. Before his work at MKMV, Stein was the Head of Research at Moody’s Risk Management Services (MRMS) where he oversaw a team of researchers focused on building products to assess various forms of corporate credit risk. At MRMS Stein and his colleagues also developed a number of methodologies for validating and testing risk model performance that have become standard approaches in industry and academia.

Dr. Stein has written over fifty professional and academic articles and serves on the editorial boards of several finance journals. He has also co-authored two full-length texts on applied analytics: Active Credit Portfolio Management in Practice (Wiley, 2009), on practical credit risk management; and Seven Methods for Transforming Corporate Data into Business Intelligence (Prentice Hall, 1997), on commercial applications of data analytics, data mining (big data) and decision systems. Stein is a frequent invited speaker at industry, academic and regulatory venues.

In addition to his professional work he the founder and president of the Consortium for Systemic Risk Analytics and a member of the Advisory Council of the Museum of Mathematics; the Board of PlaNet Finance, USA, and the Academic Advisory Board of the EC’s SYstemic Risk Tomography Project (SYRTO).

Dr. Stein holds a Ph.D. and Masters degree from the Stern School of Business, New York University, and a Bachelors degree in Mathematics and Japanese Studies from the State University of New York at Binghamton, with undergraduate minors in Russian and East Asian Studies. He has been practicing Aikido since 1980.

Vikas P. Sukhatme MD PhD is the Victor J. Aresty Professor of Medicine at Harvard Medical School, and Chief Academic Officer and Harvard Faculty Dean for Academic Programs at Beth Israel Deaconess Medical Center.

He holds a doctorate in physics from MIT and an MD from Harvard. His research contributions span numerous areas of medicine and are in both basic science and clinical arenas. His longstanding interest in cancer currently centers around tumor metabolism and tumor immunology and on “outside-of-the-box” approaches for treating advanced cancer. He has conducted studies on genes important in kidney cancer. He was part of the team that uncovered the cause of preeclampsia, a blood vessel disorder and a major cause of morbidity in pregnant women. His research has provided insights into how blood vessels leak in patients with severe infections and on how new vessels form to feed growing tumors. He has elucidated mechanisms by which statins can cause muscle damage. Finally, he is a co-founder of a not-for-profit organization, GlobalCures, whose goal is to conduct clinical trials on promising therapies for cancer not being pursued for lack of profitability.

Marty Tenenbaum, Cancer Commons. Please see Steering Committee tab for bio.

Jake Xia, Harvard Management Company. Please see Steering Committee tab for bio.

Material presented at CanceRx 2014 is available to conference participants only. Please CLICK HERE to access the password-protected area.